% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Cordonnier:281348,
      author       = {Cordonnier, Charlotte and Klijn, Catharina and Smith, Eric
                      Edward and Al-Shahi Salman, Rustam and Chwalisz, Bart K and
                      van Etten, Ellis and Muir, Ryan T and Piazza, Fabrizio and
                      Schreiber, Stefanie and Schreuder, Floris Hbm and Selim,
                      Magdy and Shoamanesh, Ashkan and Viswanathan, Anand and
                      Wermer, Marieke and Zandi, Michael and Charidimou, Andreas
                      and Greenberg, Steven M and Werring, David},
      title        = {{D}iagnosis and management of cerebral amyloid angiopathy:
                      a scientific statement from the {I}nternational {CAA}
                      {A}ssociation and the {W}orld {S}troke {O}rganization.},
      journal      = {International journal of stroke},
      volume       = {20},
      number       = {8},
      issn         = {1747-4930},
      address      = {London},
      publisher    = {Sage},
      reportid     = {DZNE-2025-01095},
      pages        = {949 - 967},
      year         = {2025},
      abstract     = {Cerebral amyloid angiopathy (CAA) is a well-recognized and
                      challenging disease for neurologists and other clinicians
                      caring for the rapidly aging worldwide population. CAA is a
                      major cause of spontaneous lobar intracerebral hemorrhage
                      (ICH), and can also cause transient focal neurological
                      episodes, and convexity subarachnoid hemorrhage,
                      CAA-associated ICH has a high mortality, morbidity, and
                      recurrence rate. CAA can affect a wide range of clinical
                      decisions including use of antithrombotic medications,
                      safety for anti-β-amyloid peptide (Aβ) immunotherapy, and
                      need for anti-inflammatory or immunosuppressive treatment.
                      We present guidelines, intended to inform the approach to
                      individuals with suspected CAA, written on behalf of the
                      International CAA Association and the World Stroke
                      Organization (WSO). We cover five areas selected for their
                      relevance to practice: (1) diagnosis, testing, and
                      prediction of intracerebral hemorrhage risk; (2)
                      antithrombotic agents and vascular interventions; (3)
                      vascular risk factors and concomitant medications; (4)
                      treatment of CAA manifestations; and (5) diagnosis and
                      treatment of CAA-related inflammation and vasculitis. The
                      statement has been reviewed and approved by the Executive
                      Committee of the WSO, and the International CAA
                      Association.},
      subtyp        = {Review Article},
      keywords     = {Humans / Cerebral Amyloid Angiopathy: diagnosis / Cerebral
                      Amyloid Angiopathy: therapy / Cerebral Amyloid Angiopathy:
                      complications / Disease Management / Cerebral Hemorrhage:
                      etiology / Cerebral Hemorrhage: therapy / Cerebral
                      Hemorrhage: diagnosis / Stroke: therapy / Stroke: diagnosis
                      / Risk Factors / Fibrinolytic Agents: therapeutic use /
                      Societies, Medical / MRI (Other) / antithrombotic (Other) /
                      brain bleed (Other) / brain microbleeds (Other) / cerebral
                      hemorrhage (Other) / leukoaraiosis (Other) / Fibrinolytic
                      Agents (NLM Chemicals)},
      cin          = {AG Schreiber},
      ddc          = {610},
      cid          = {I:(DE-2719)1310010},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40721902},
      doi          = {10.1177/17474930251365861},
      url          = {https://pub.dzne.de/record/281348},
}